1932

Abstract

For benefit-cost analysis of policies with respect to environmental and natural resources, economic researchers often require monetized values of households’ willingness to pay for reductions in risks to human life and health. I briefly recap some of the main issues in the related task of valuing reductions in the risk of death. These issues also account for our considerably smaller literature on valuing reductions in morbidity risks. An important distinction is the issue of valuation in the space of illnesses versus valuation in the space of illness attributes. I compare the requirements for environmental benefit-cost analysis with the limitations of the standard approaches taken in cost-effectiveness analysis in health economics, and I highlight some areas that are ripe for further research.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-resource-091912-151943
2014-10-05
2024-10-12
Loading full text...

Full text loading...

/deliver/fulltext/resource/6/1/annurev-resource-091912-151943.html?itemId=/content/journals/10.1146/annurev-resource-091912-151943&mimeType=html&fmt=ahah

Literature Cited

  1. Adamowicz W, Dupont D, Krupnick A, Zhang J. 2011. Valuation of cancer and microbial disease risk reductions in municipal drinking water: an analysis of risk context using multiple valuation methods. J. Environ. Econ. Manag. 61:2213–26 [Google Scholar]
  2. Alberini A, Scasny M. 2011. Context and the VSL: evidence from a stated preference study in Italy and the Czech Republic. Environ. Resour. Econ. 49:4511–38 [Google Scholar]
  3. Bansback N, Brazier J, Tsuchiya A, Anis A. 2012a. Using a discrete choice experiment to estimate health state utility values. J. Health Econ. 31:1306–18 [Google Scholar]
  4. Bansback N, Tsuchiya A, Brazier J, Anis A. 2012b. Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies. PLOS ONE 7:2e31115 [Google Scholar]
  5. Bellavance F, Dionne G, Lebeau M. 2009. The value of a statistical life: a meta-analysis with a mixed effects regression model. J. Health Econ. 28:2444–64 [Google Scholar]
  6. Bleichrodt H, Quiggin J. 1999. Life-cycle preferences over consumption and health: When is cost-effectiveness analysis equivalent to cost-benefit analysis?. J. Health Econ. 18:6681–708 [Google Scholar]
  7. Blomquist GC, Dickie M, O'Conor RM. 2011. Willingness to pay for improving fatality risks and asthma symptoms: values for children and adults of all ages. Resour. Energy Econ. 33:2410–25 [Google Scholar]
  8. Bosworth RC, Cameron TA, DeShazo JR. 2009. Demand for environmental policies to improve health: evaluating community-level policy scenarios. J. Environ. Econ. Manag. 57:3293–308 [Google Scholar]
  9. Bosworth RC, Cameron TA, DeShazo JR. 2013. Willingness to pay for public health policies to treat illnesses. Work. Pap., Dep. Econ., Univ. Or., Eugene
  10. Brandt S, Lavin FV, Hanemann M. 2012. Contingent valuation scenarios for chronic illnesses: the case of childhood asthma. Value Health 15:81077–83 [Google Scholar]
  11. Brazier J, Roberts J, Deverill M. 2002. The estimation of a preference-based measure of health from the SF-36. J. Health Econ. 21:2271–92 [Google Scholar]
  12. Bridges JFP, Hauber AB, Marshall D, Lloyd A, Prosser LA et al. 2011. Conjoint analysis applications in health—a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health 14:4403–13 [Google Scholar]
  13. Brooks R. 1996. EuroQol: the current state of play. Health Policy 37:153–72 [Google Scholar]
  14. Cai BL, Cameron TA, Gerdes GR. 2010. Distributional preferences and the incidence of costs and benefits in climate change policy. Environ. Resour. Econ. 46:4429–58 [Google Scholar]
  15. Cameron TA. 2010. Euthanizing the value of a statistical life. Rev. Environ. Econ. Policy 4:2161–78 [Google Scholar]
  16. Cameron TA, DeShazo JR. 2010. Differential attention to attributes in utility-theoretic choice models. J. Choice Model. 3:373–115 [Google Scholar]
  17. Cameron TA, DeShazo JR. 2013. Demand for health risk reductions. J. Environ. Econ. Manag. 65:187–109 [Google Scholar]
  18. Cameron TA, DeShazo JR, Johnson EH. 2010a. The effect of children on adult demands for health-risk reductions. J. Health Econ. 29:3364–76 [Google Scholar]
  19. Cameron TA, DeShazo JR, Johnson EH. 2010b. Willingness to pay for health risk reductions: differences by type of illness. Work. Pap., Dep. Econ., Univ. Or., Eugene
  20. Cropper M, Hammitt JK, Robinson LA. 2011. Valuing mortality risk reductions: progress and challenges. Annu. Rev. Resour. Econ 3:313–36 [Google Scholar]
  21. Davies AR, Smeeth L, Grundy EM. 2007. Contribution of changes in incidence and mortality to trends in the prevalence of coronary heart disease in the UK: 1996–2005. Eur. Heart J. 28:172142–47 [Google Scholar]
  22. de Bekker-Grob EW, Ryan M, Gerard K. 2012. Discrete choice experiments in health economics: a review of the literature. Health Econ. 21:2145–72 [Google Scholar]
  23. Dekker T, Brouwer R, Hofkes M, Moeltner K. 2011. The effect of risk context on the value of a statistical life: a Bayesian meta-model. Environ. Resour. Econ. 49:4597–624 [Google Scholar]
  24. DeShazo JR, Cameron TA. 2005. The effect of health status on willingness to pay for morbidity and mortality risk reductions. Work. Pap., Dep. Econ., Univ. Or., Eugene
  25. Diamond PA, Hausman JA. 1994. Contingent valuation: Is some number better than no number?. J. Econ. Perspect. 8:445–64 [Google Scholar]
  26. Dolan P. 1997. Modeling valuations for EuroQol health states. Med. Care 35:111095–108 [Google Scholar]
  27. Doucouliagos C, Stanley TD, Giles M. 2012. Are estimates of the value of a statistical life exaggerated?. J. Health Econ. 31:1197–206 [Google Scholar]
  28. Eckert C, Louviere JJ, Islam T. 2012. Seeing the forest despite the trees: brand effects on choice uncertainty. Int. J. Res. Mark. 29:3256–64 [Google Scholar]
  29. Gyrd-Hansen D, Kjaer T. 2012. Disentangling WTP per QALY data: different analytical approaches, different answers. Health Econ. 21:3222–37 [Google Scholar]
  30. Haab TC, Interis MG, Petrolia DR, Whitehead JC. 2013. From hopeless to curious? Thoughts on Hausman’s “dubious to hopeless” critique of contingent valuation. Appl. Econ. Perspect. Policy 35:4593–612 [Google Scholar]
  31. Hammitt JK, Ibarraran ME. 2006. The economic value of fatal and non-fatal occupational risks in Mexico City using actuarial- and perceived-risk estimates. Health Econ. 15:121329–35 [Google Scholar]
  32. Hauber AB, Bridges JFP, Cunningham C, González JM, Groothuis-Oudshoorn KGM et al. 2014. Conjoint analysis—statistical analyses, results and conclusions. Good Research Practices Task Force. Value Health. In press [Google Scholar]
  33. Hauber AB, González JM, Schenkel B, Lofland JH, Martin S. 2011. The value to patients of reducing lesion severity in plaque psoriasis. J. Dermatol. Treat. 22:266–75 [Google Scholar]
  34. Hauber AB, Han S, Yang JC, Gantz I, Tunceli K et al. 2013. Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes. Patient Prefer. Adher. 7:937–49 [Google Scholar]
  35. Hausman J. 2012. Contingent valuation: from dubious to hopeless. J. Econ. Perspect. 26:443–56 [Google Scholar]
  36. Hensher DA, Rose JM, Ortuzar JD, Rizzi LI. 2009. Estimating the willingness to pay and value of risk reduction for car occupants in the road environment. Transp. Res. A 43:7692–707 [Google Scholar]
  37. Hugonnier J, Pelgrin F, St-Amour P. 2013. Health and (other) asset holdings. Rev. Econ. Stud. 80:2663–710 [Google Scholar]
  38. Hultkrantz L, Lindberg G, Andersson C. 2006. The value of improved road safety. J. Risk Uncertain. 32:2151–70 [Google Scholar]
  39. Hurley J, Mentzakis E. 2013. Health-related externalities: evidence from a choice experiment. J. Health Econ. 32:4671–81 [Google Scholar]
  40. Iskedjian M, Desjardins O, Piwko C, Bereza B, Jaszewski B, Einarson TR. 2009. Willingness to pay for a treatment for pain in multiple sclerosis. Pharmacoeconomics 27:2149–58 [Google Scholar]
  41. Jacobs N, Drost R, Ament A, Evers S, Claes N. 2011. Willingness to pay for a cardiovascular prevention program in highly educated adults: a randomized controlled trial. Int. J. Technol. Assess. Health Care 27:4283–89 [Google Scholar]
  42. Johnson FR. 2009. Editorial: moving the QALY forward or just stuck in traffic?. Value Health 12:S38–39 [Google Scholar]
  43. Johnson FR, Lancsar E, Marshall D, Kilambi V, Muhlbacher A et al. 2013. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health 16:13–13 [Google Scholar]
  44. Johnston SS, Rousculp MD, Palmer LA, Chu BC, Mahadevia PJ, Nichol KL. 2010. Employees’ willingness to pay to prevent influenza. Am. J. Manag. Care 16:8E205–14 [Google Scholar]
  45. King JT, Tsevat J, Lave JR, Roberts MS. 2005. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med. Decis. Making 25:6667–77 [Google Scholar]
  46. Kling CL, Phaneuf DJ, Zhao JH. 2012. From Exxon to BP: Has some number become better than no number?. J. Econ. Perspect. 26:43–26 [Google Scholar]
  47. Kniesner TJ, Viscusi WK, Woock C, Ziliak JP. 2012. The value of a statistical life: evidence from panel data. Rev. Econ. Stat. 94:174–87 [Google Scholar]
  48. Kniesner TJ, Viscusi WK, Ziliak JP. 2010. Policy relevant heterogeneity in the value of statistical life: new evidence from panel data quantile regressions. J. Risk Uncertain. 40:115–31 [Google Scholar]
  49. Kochi I, Hubbell B, Kramer R. 2006. An empirical Bayes approach to combining and comparing estimates of the value of a statistical life for environmental policy analysis. Environ. Resour. Econ. 34:3385–406 [Google Scholar]
  50. Lancsar E, Wildman J, Donaldson C, Ryan M, Baker R. 2011. Deriving distributional weights for QALYs through discrete choice experiments. J. Health Econ. 30:2466–78 [Google Scholar]
  51. Lang HC. 2010. Willingness to pay for lung cancer treatment. Value Health 13:6743–49 [Google Scholar]
  52. Lang HC, Chang K, Ying YH. 2012. Quality of life, treatments, and patients' willingness to pay for a complete remission of cervical cancer in Taiwan. Health Econ. 21:101217–33 [Google Scholar]
  53. Li CY, Zeliadt SB, Hall IJ, Smith JL, Ekwueme DU et al. 2012. Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosis. Value Health 15:5716–23 [Google Scholar]
  54. Lloyd A, McIntosh E, Price M. 2005. The importance of drug adverse effects compared with seizure control for people with epilepsy—a discrete choice experiment. Pharmacoeconomics 23:1167–81 [Google Scholar]
  55. Longo CJ. 1999. Choices of methodology in pharmacoeconomic studies. Med. Care 37:4AS32–35 [Google Scholar]
  56. Marti J. 2012. Assessing preferences for improved smoking cessation medications: a discrete choice experiment. Eur. J. Health Econ. 13:5533–48 [Google Scholar]
  57. Milligan MA, Bohara AK, Pagan JA. 2010. Assessing willingness to pay for cancer prevention. Int. J. Health Care Finance Econ. 10:4301–14 [Google Scholar]
  58. Mrozek JR, Taylor LO. 2002. What determines the value of life? A meta-analysis. J. Policy Anal. Manag. 21:2253–70 [Google Scholar]
  59. National Research Council 2006. Valuing Health for Regulatory Cost-Effectiveness Analysis. Washington, DC: Natl. Acad. Press [Google Scholar]
  60. Norman RPA. 2012. Outcome valuation in the economic evaluation of healthcare. PhD thesis, Univ. Technol., Sydney
  61. Oh DY, Crawford B, Kim SB, Chung HC, McDonald J et al. 2012. Evaluation of the willingness-to-pay for cancer treatment in Korean metastatic breast cancer patients: a multicenter, cross-sectional study. Asia Pac. J. Clin. Oncol. 8:3282–91 [Google Scholar]
  62. Ozdemir S, Johnson FR. 2013. Estimating willingness to pay: Do health and environmental researchers have different methodological standards?. Appl. Econ. 45:162215–29 [Google Scholar]
  63. Pickard AS, Tawk R, Shaw JW. 2013. The effect of chronic conditions on stated preferences for health. Eur. J. Health Econ. 14:4697–702 [Google Scholar]
  64. Prosser LA, Payne K, Rusinak D, Shi P, Messonnier M. 2013. Using a discrete choice experiment to elicit time trade-off and willingness-to-pay amounts for influenza health-related quality of life at different ages. Pharmacoeconomics 31:4305–15 [Google Scholar]
  65. Richardson L, Loomis JB, Champ PA. 2013. Valuing morbidity from wildfire smoke exposure: a comparison of revealed and stated preference techniques. Land Econ. 89:176–100 [Google Scholar]
  66. Schaffner S, Spengler H. 2010. Using job changes to evaluate the bias of value of a statistical life estimates. Resour. Energy Econ. 32:115–27 [Google Scholar]
  67. Scotton CR, Taylor LO. 2011. Valuing risk reductions: incorporating risk heterogeneity into a revealed preference framework. Resour. Energy Econ. 33:2381–97 [Google Scholar]
  68. Seidler AM, Bayoumi AM, Goldstein MK, Cruz PD, Chen SC. 2012. Willingness to pay in dermatology: assessment of the burden of skin diseases. J. Investig. Dermatol. 132:71785–90 [Google Scholar]
  69. Servan-Mori EE, Heredia-Pi IB, Reynales-Shigematsu LM, Bautista-Arredondo S. 2012. Smoking cessation interventions in Mexico: analysis of the willingness to pay for an effective method to quit. Salud Publica Mex. 54:3213–24 [Google Scholar]
  70. Suh HS, Kim Y, Park J, Park S, Hyun MK, Ahn J. 2011. Willingness to pay for osteoporosis treatment to prevent fracture in Korean population. Value Health 14:3A131 [Google Scholar]
  71. Swait J, Erdem T. 2007. Brand effects on choice and choice set formation under uncertainty. Mark. Sci. 26:5679–97 [Google Scholar]
  72. Thaler RH, Sunstein CR. 2003. Libertarian paternalism. Am. Econ. Rev. 93:2175–79 [Google Scholar]
  73. Tilling C, Devlin N, Tsuchiya A, Buckingham K. 2010. Protocols for time tradeoff valuations of health states worse than dead: a literature review. Med. Decis. Mak. 30:5610–19 [Google Scholar]
  74. US EPA. 2005. Environmental economics research strategy. Off. Res. Dev., Natl. Cent. Environ. Res., US EPA, Washington, DC
  75. van Houtven G, Smith VK. 1999. Willingness to pay for reductions in infertility risks: a contingent valuation study. Work. Pap. presented at EPA Workshop entitled Valuing Health for Environmental Policy with Special Emphasis on Children’s Health Protection, Silver Spring, Md., March 25
  76. Viney R, Savage E. 2005. Health care policy evaluation: empirical analysis of the restrictions implied by Quality Adjusted Life Years. CHERE Work. Pap., Fac. Bus., Univ. Technol., Sydney
  77. Viscusi WK. 2012. What’s to know? Puzzles in the literature on the value of statistical life. J. Econ. Surv. 26:5763–68 [Google Scholar]
  78. Viscusi WK, Aldy JE. 2003. The value of a statistical life: a critical review of market estimates throughout the world. J. Risk Uncertain. 27:15–76 [Google Scholar]
  79. Viscusi WK, Huber J, Bell J. 2012. Heterogeneity in values of morbidity risks from drinking water. Environ. Resour. Econ. 52:123–48 [Google Scholar]
/content/journals/10.1146/annurev-resource-091912-151943
Loading

Supplementary Data

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error